Safety and Efficacy Study of Nitazoxanide in the Treatment of Acute Uncomplicated Influenza
Status:
Completed
Trial end date:
2015-04-16
Target enrollment:
Participant gender:
Summary
This study is a global multicenter randomized factorial double-blind, placebo-controlled
trial designed to evaluate (i) efficacy and safety of nitazoxanide 600 mg administered orally
twice daily for five days compared to a placebo in the treatment of acute uncomplicated
influenza and (ii) efficacy and safety of combination therapy with nitazoxanide 600 mg plus
Oseltamivir 75 mg co-administered orally twice daily for five days compared to nitazoxanide
monotherapy (600 mg b.i.d. for 5 days) and Oseltamivir monotherapy (75 mg b.i.d. for 5 days)
in the treatment of acute uncomplicated influenza.